Substantial pipeline and partnering
assets and opportunities

The Amphiphile platform precisely concentrates a variety of different Immunogens in the lymph nodes to maximally impact the immune response, while conventional vaccines, adjuvants, and other immunotherapies are systemically distributed, thus limiting their ability to influence immunity in the body’s natural centers of immune action. The Amphiphile vaccine approach is also being used in concert with novel cellular therapies to utilize the lymph nodes to enhance the effectiveness of cell therapy and address the critical challenges these therapies face. Elicio is building a broad pipeline of candidates including cancer vaccines and adjuvants, cellular therapy vaccines, cytokines, and co-stimulatory candidates which all concentrate in the lymph nodes, to powerfully orchestrate anti-cancer immunity, with tremendous capital efficiency and speed. Elicio’s lead cancer vaccine and adjuvant programs will enter initial patient studies in the first half of 2020.